STATUS Recruitment Complete

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (PALISADES-1)

Kite Clinical Study Information Center:
Monday – Friday, 5am – 6pm PT
Email:  

Kite Clinical Study Information Center:
Monday – Friday, 5am – 6pm PT
Email:  

LAST UPDATED

October 28, 2026

Clinicaltrials.gov ID

NCT04989803

EudraCT ID

2020-000562-41

OVERVIEW

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (PALISADES-1)

PROTOCOL SUMMARY

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

View more

Participation requirements

Calendar

Age

18 years +

Condition

Sex

All

Healthy Icon

Healthy Volunteers

No

Study details

Medical Condition

Relapsed and/or Refractory B-cell Lymphoma

Gender

N/A

Date

October 2021 - February 2030

Study Type

Interventional

Study Phase

Phase 1, Phase 2

Product

Cyclophosphamide, Fludarabine, KITE-363, KITE-753

Eligibility information

Inclusion

Inclusion criteria

  • Relapsed and/or refractory B-cell lymphoma (R/R BCL).
  • At least 1 measurable lesion.
  • Adequate organ and bone marrow (BM) function.
VIEW MORE arrow
Exclusion

Exclusion criteria

  • History of chimeric antigen receptor (CAR) therapy or other genetically modified T cell therapy.
  • Phase 1b Cohort D only: Absolute lymphocyte count ≥ 20,000/μL.
  • History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, or breast) unless disease free and without anticancer therapy (with the exception of hormonal therapy in the case of breast cancer) for at least 3 years.
  • History of allogeneic stem cell transplant (allo-SCT).
  • Auto-SCT within 6 weeks before the planned KITE-363 or KITE-753 infusion.
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requires intravenous (IV) antimicrobials for management.
  • Known history of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) (hepatitis B surface [HBs] antigen [HBsAg] positive) infection, or hepatitis C (anti-hepatitis C virus [HCV] positive) infection. History of a hepatitis B or C infection is permitted if the viral load is undetectable per quantitative polymerase chain reaction (qPCR) or nucleic acid testing.
  • Individuals with suspicion and/or evidence of primary or secondary CNS lymphoma.
  • History or presence of a CNS disorder.
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, active arrhythmia, New York Heart Association Class II or greater congestive heart failure or other clinically significant cardiac disease within the 6 months before enrollment.
  • Primary immunodeficiency.
  • History of autoimmune disease resulting in or requiring systemic immunosuppression and/or systemic disease-modifying agents within the last 90 days.
  • Individuals with concern for gastric or intestinal perforation or known contained perforation.
  • Females of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or have been postmenopausal for at least 2 years are not considered to be of childbearing potential.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.
VIEW MORE arrow

Locations

Locations (36)

Other

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States, 85234

Email:  

Other

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, United States, 91010

Email:  

Other

Stanford Cancer Institute

Stanford, California, United States, 94305

Email:  

Other

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224

Email:  

Other

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Email:  

Other

Northside Hospital

Atlanta, Georgia, United States, 30342

Email:  

Other

University of Illinois Chicago

Chicago, Illinois, United States, 60618

Email:  

Other

Midwestern Regional Medical Center, Inc.City of Hope Chicago

Park Ridge, Illinois, United States, 60068

Email:  

Other

Norton Cancer Institute, St. Matthews Campus

Shelbyville, Kentucky, United States, 40065

Email:  

Other

University of MD, Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States, 21201

Email:  

Other

Mayo Clinic

Rochester, Minnesota, United States, 55905

Email:  

Other

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Email:  

Other

Columbia University Irving Medical Center

New York, New York, United States, 10032

Email:  

Other

University of Rochester Medical Center

Rochester, New York, United States, 14642

Email:  

Other

The Ohio State University Wexner Medical Center - James Cancer Hospital

Columbus, Ohio, United States, 43210

Email:  

Other

Tennessee Oncology, PLLC - Investigational Drug Services

Nashville, Tennessee, United States, 37203

Email:  

Other

Vanderbilt University

Nashville, Tennessee, United States, 37232

Email:  

Other

St. David's Medical Center

Austin, Texas, United States, 78704

Email:  

Other

The University of Texas, MD Anderson Cancer Center

Houston, Texas, United States, 77030

Email:  

Other

Virginia Oncology Associates

Norfolk, Virginia, United States, 23502

Email:  

Other

Swedish Cancer Institute

Seattle, Washington, United States, 98104

Email:  

Other

Royal North Shore Hospital

St Leonards, New South Wales, Australia, 2065

Email:  

Other

Concord Repatriation General Hospital

Sydney, New South Wales, Australia, 2139

Email:  

Other

Royal Adelaide Hospital

Adelaide, South Australia, Australia, 5000

Email:  

Other

Monash Health, Monash Medical Centre

Clayton, Victoria, Australia, 3168

Email:  

Other

Epworth Healthcare

East Melbourne, Victoria, Australia, 3002

Email:  

Other

St. Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia, 3065

Email:  

Other

Cross Cancer Center

Edmonton, Canada, T6G 1Z2

Email:  

Other

Queen Elizabeth II Health Sciences Centre

Halifax, Canada, B3H 2Y9

Email:  

Other

Jewish General Hospital

Montreal, Canada, H3T 1E2

Email:  

Other

McGill University Health Center

Montreal, Canada, H4A 0B1

Email:  

Other

Princess Margaret Cancer Centre - University Health Network

Toronto, Canada, M5G 2C4

Email:  

Other

Universitatsklinikum Wurzburg

Würzburg, Germany, 97080

Email:  

Other

Academisch Medisch Centrum

Amsterdam, Netherlands, 1105 AZ

Email:  

Other

Universitair Medisch Centrum Groningen

Groningen, Netherlands, 9700 RB

Email:  

Other

King's College Hospital

London, United Kingdom, SE5 9RS

Email: